Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Table: Troubling Symptoms for CEO McKinnell


TOUGHER COMPETITION

AstraZeneca (AZN) will launch a cholesterol-lowering drug later this year to compete with Pfizer's $6.4 billion Lipitor. And new treatments for erectile dysfunction could hurt $1.5 billion Viagra.

DWINDLING COST SAVINGS

It will be hard to top the $1.4 billion savings Pfizer (PFE) achieved in 2001, or the $300 million it expects to save this year, after its acquisition of Warner-Lambert.

FEW BIG NEW PRODUCTS

Pfizer has some possible blockbusters coming, such as pregabalin, which treats epilepsy and neuropathic pain. But an eagerly anticipated inhaled insulin drug has been delayed at least a year.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus